Dr. Christopher Venner

Assistant Professor

Department of Oncology

Division of Medical Oncology

Office Phone Number: (780) 432-8757
cvenner@ualberta.ca

Contact details are for academic matters only.

About Me

Dr. Christopher Venner is currently appointed as Assistant Professor in the Division of Medical Oncology in the Faculty of Medicine and Dentistry.

Research

Myeloma, Waldenstroms macroglobulinemia, Amyloidosis, Drug Development, Stem Cell Transplantation, Correlative Biology, Genomics

Research Keywords

Canada, Database, Myeloma, Real world evidence

- DETECTION OF MINIMAL RESIDUAL DISEASE IN AUTOGRAFT IS PROGNOSTIC OF SURVIVAL FOLLOWING STEM CELL TRANSPLANT IN MULTIPLE MYELOMA
- Author(s): Chu MP, Baigorri E, Kriangkum J, Hewitt J, Belch AR, Venner CP, Sandhu I, Pilarski LM
- Journal: Other
- Publication Year: 2018
- TARGETING DNA DAMAGE RESPONSE IN MULTIPLE MYELOMA
- Author(s): Smith J, Venner CP, Ismail I
- Journal: Other
- Publication Year: 2018
- THE EVOLVING IMPACT ON SURVIVAL OUTCOMES IN MULTIPLE MYELOMA WITH GREATER ACCESS TO NOVEL TREATMENT REGIMENS: EXPERIENCE IN A REAL-WORLD COHORT.
- Author(s): Breckenridge Z, Jimenez-Zepeda V, Bahlis NJ, Neri EP, Sandhu I, Chu MP, Ismail I, Tay J, Duggan P, Belch AR, Hewitt JD, Pilarski LM, Nikitina T, Venner CP
- Journal: Other
- Publication Year: 2018
- DETECTION OF MINIMAL RESIDUAL DISEASE IN AUTOGTAFT IS PROGNOSTIC OF SURVIVAL FOLLOWING STEM CELL TRANSPLANT IN MULTIPLE MYELOMA.
- Author(s): Chu MP, Baigorri E, Kriangkum J, Hewitt JD, Belch AR, Venner CP, Sandhu I, Pilarski LM
- Journal: BLOOD
- Publication Year: 2018
- THE SURVIVAL IMPACT OF LENALIDOMIDE MAINTENANCE CHEMOTHERAPY IN MULTIPLE MYELOMA PATIENTS WITH AUTOLOGOUS STEM CELL TRANSPLANT AND BORTEZOMIB-BASED INDUCTION: AN ANALYSIS OF REAL WORLD DATA.
- Author(s): Cherniawsky H, Sandhu I, Chu MP, Hewitt JD, Ismail I, Belch AR, Pilarski LM, Nikitina T, Venner CP
- Journal: BLOOD
- Publication Year: 2018
- THE EVOLVING IMPACT ON SURVIVAL OUTCOMES IN MULTIPLE MYELOMA WITH GREATER ACCESS TO NOVEL TREATMENT REGIMENS: EXPERIENCE IN A REAL-WORLD COHORT.
- Author(s): Breckenridge ZM, Jimenez-Zepeda V, Bahlis NJ, Neri EP, Sandhu I, Chu MP, Ismail I, JTay J, Duggan P, Belch A, Hewitt JD, Pilarski LM, Nikitina T, Venner CP
- Journal: BLOOD
- Publication Year: 2018
- DARATUMUMAB MONOTHERAPY FOR PATIENTS WITH INTERMEDIATE OR HIGH-RISK SMOLDERING MULTIPLE MYELOMA (SMM): CENTAURUS, A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY.
- Author(s): Hofmeister CC, Chari A, Cohen Y, Spencer A, Voorhees PM, Estell J, Venner CP, Sandhu I, Jenner MW, Williams C, Cavo M, Van De Donk NWCJ, Beksac M, Kuppens S, Bandekar R, Neff T, Heuck C, Qi M, Goldschmidt H, Landgren O
- Journal: BLOOD
- Publication Year: 2018
- SELINEXOR IN COMBINATION WITH POMALIDOMIDE AND LOW DOSE DEXAMETHASONE IN A RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENT POPULATION WITH PRIOR PROTEOSOME INHIBITOR AND LENALIDOMIDE EXPOSURE.
- Author(s): Chen CI, Sutherland HJ, Kotb R, Sebag M, White DJ, Bensinger W, Gasparetto CJ, LeBlanc R, Venner CP, Lentzsch S, Schiller GJ, Lipe BC, Del Col A, Kauffman MG, Shacham S, Jeha J, Saint-Martin JR, Jatin J Shah, Bahlis NJ
- Journal: BLOOD
- Publication Year: 2018
- SELINEXOR IN COMBINATION WITH WEEKLYY LOW DOSE DEXAMETHASONE (SVD) INDUCES A HIGH RESPONSE RATE WITH DURABLE RESPONSE RATE AND DURABLE RESPONSES IN PATIENTS WITH REFRACTORY MULTIPLE MYELOMA (MM).
- Author(s): Bahlis NJ, Sutherland HJ, Darrell White DJ, Sebag M, Lentzsch S, Kotb R, Venner CP, Gasparetto CJ, Schiller GJ, LeBlanc R, Bensinger W, Lipe B, Del Col A, Kauffman MG, Shacham S, Jeha J, Saint-Martin JR, Shah J, Chen CI
- Journal: BLOOD
- Publication Year: 2018
- A PHASE 1V STUDY TO ASSESS THE COMBINATION OF SELINEXOR AND DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORYMULTIPLE MYELOMA PREVIOUSLY EXPOSED TO PROTEOSOME INHIBITORS (PI) AND IMMUNOMODULATORY DRUGS (IMIDS).
- Author(s): Gasparetto CJ, Lentzsch S, Schiller GJ, Bensinger W, Bahlis NJ, Sutherland HJ, White DJ, Sebag M, Kotb R, Venner CP, LeBlanc R, Chen CI, Del Col A, Kauffman MG, Shacham S, Jeha J, Saint-Martin JR, Shah J, Lipe BC
- Journal: BLOOD
- Publication Year: 2018
- A PHASEIB/II TRIAL OF SELINEXOR COMBINED WITH LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA.
- Author(s): White DJ, Bahlis NJ, Venner CP, Schiller GJ, Gasparetto CJ, Sutherland HJ, Sebag M, Lentzsch S, Kotb R, Bensinger W, Lipe BC, Chen CI, Del Col A, Kauffman MG, Shacham S, Jeha J, Saint-Martin JR, Shah J, Le Blanc R
- Journal: Other
- Publication Year: 2018
- TARGETED-CAPTURE SEQUENCING APPROACH TO V(D)J REARRANGEMENT, IMMUNOGLOBULIN (IG) TRANSLOCATION AND MUTATION DETECTIONIN MULITPLE MYELOMA (MM): POTENTIAL APPLICATIONS IN MINIMAL RESIDUAL DISEASE (MRD) ANALYSIS AND COMPARISON TO MULTIPARAMETER FLOW CYTOMETRY (MFC) IN THE MYELOMA CANADA RESEARCH NETWORK (MCRN) 001 STUDY WITH INTRAVENOUS BUSULFAN AND MELPHALAN (BUMEL) CONDITIONING FOLLOWED BY LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM).
- Author(s): Chow S, Reece DE, Keats JJ, Bergsagel PL, Bahlis NJ, Neri EP, Piza Rodriguez G, Sebag M, White DJ, Song KW, Comeau T, Venner CP, Chen CI, Roy J, Louzada ML, Stakiw J, Kew A, Kukreti V, Prica A, Tiedemann R, Pantoja MA, Paul HK, Pugh TJ, Trudel S
- Journal: BLOOD
- Publication Year: 2018
- A PHASEIB/II TRIAL OF SELINEXOR COMBINED WITH LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA.
- Author(s): White DJ, Bahlis NJ, Venner CP, Schiller GJ, Gasparetto CJ, Sutherland HJ, Sebag M, Lentzsch S, Kotb R, Bensinger W, Lipe BC, Chen CI, Del Col A, Kauffman MG, Shacham S, Jeha J, Saint-Martin JR, Shah J, Le Blanc R
- Journal: BLOOD
- Publication Year: 2018
- A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY OF DARATUMUMAB MONOTHERAPY FOR PATIENTS WITH INTERMEDIATE OR HIGH-RISK SMOLDERING MULITPLE MYELOMA (SMM): CENTAURUS.
- Author(s): Vorhees P, Estell J, Venner CP, Sandhu I, Jenner M , Williams C, van de Donk N, Beksac M, Kuppens S., Bandekar R, Neff T, Heuck C, Qi M, Goldschmidt H, Ola Landgren C
- Journal: Other
- Publication Year: 2018
- THE MYELOMA CANADA RESEARCH NETWORK CANADIAN MULTIPLE MYELOMA DATABASE (MCRN CMM-DB): MULTI-INSTITUTIONAL SHARING OF CLINICAL DATA FOR RESEARCH.
- Author(s): Venner CP, Masih-Kahn E, Truon T, Jimenez-Zepeda V, McCurdy A, Sebag M, Song K, Reiman T, LeBlanc R, Stakiw J, Louzada M, Kotb R, White D, Aslam M, Del Col A, Tavoularis S, Gul E, Reece DE
- Journal: Other
- Publication Year: 2018
- CARDIAC REHABILITATION IN LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOETIC STEM CELL TRANSPLANTATION: A CARDIOONCOLOGY PILOT STUDY.
- Author(s): Rothe D, Cox-Kennett N, Buijs D, Venner CP, Paterson I, Gyenes G, Pituskin, E
- Journal: CAN J CARDIOL
- Publication Year: 2018
- Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model.
- Author(s): Huang YH, Molavi O, Alshareef A, Haque M, Wang Q, Chu MP, Venner CP, Sandhu I, Peters AC, Lavasanifar A, Lai R,
- Journal: CANCERS
- Volume: 10
- Issue: 6
- Publication Year: 2018
- PMID: 29914181

Faculty of Medicine & Dentistry

Faculty Members

Dr. Christopher Venner

Assistant Professor

Department of Oncology

Division of Medical Oncology

About Me

Research

Research Keywords

Characterisation of Clonal Lymphocyte Biology in Malignancy

Immuno-oncologic Landscape in B-Cell Malignancies in Search of Novel Therapeutic Targets

Novel MYC Immunohistochemistry Classifier to Predict MYC Translocation by Fluorescence In Situ Hybridization in Diffuse Large B-Cell Lymphoma

Targeting DNA Repair Pathways for Multiple Myeloma

Faculty Members

Dr. Christopher Venner

Assistant Professor

Department of Oncology

Division of Medical Oncology

About Me

Research

Research Keywords

DETECTION OF MINIMAL RESIDUAL DISEASE IN AUTOGRAFT IS PROGNOSTIC OF SURVIVAL FOLLOWING STEM CELL TRANSPLANT IN MULTIPLE MYELOMA

TARGETING DNA DAMAGE RESPONSE IN MULTIPLE MYELOMA

THE EVOLVING IMPACT ON SURVIVAL OUTCOMES IN MULTIPLE MYELOMA WITH GREATER ACCESS TO NOVEL TREATMENT REGIMENS: EXPERIENCE IN A REAL-WORLD COHORT.

DETECTION OF MINIMAL RESIDUAL DISEASE IN AUTOGTAFT IS PROGNOSTIC OF SURVIVAL FOLLOWING STEM CELL TRANSPLANT IN MULTIPLE MYELOMA.

THE SURVIVAL IMPACT OF LENALIDOMIDE MAINTENANCE CHEMOTHERAPY IN MULTIPLE MYELOMA PATIENTS WITH AUTOLOGOUS STEM CELL TRANSPLANT AND BORTEZOMIB-BASED INDUCTION: AN ANALYSIS OF REAL WORLD DATA.

THE EVOLVING IMPACT ON SURVIVAL OUTCOMES IN MULTIPLE MYELOMA WITH GREATER ACCESS TO NOVEL TREATMENT REGIMENS: EXPERIENCE IN A REAL-WORLD COHORT.

DARATUMUMAB MONOTHERAPY FOR PATIENTS WITH INTERMEDIATE OR HIGH-RISK SMOLDERING MULTIPLE MYELOMA (SMM): CENTAURUS, A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY.

SELINEXOR IN COMBINATION WITH POMALIDOMIDE AND LOW DOSE DEXAMETHASONE IN A RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENT POPULATION WITH PRIOR PROTEOSOME INHIBITOR AND LENALIDOMIDE EXPOSURE.

SELINEXOR IN COMBINATION WITH WEEKLYY LOW DOSE DEXAMETHASONE (SVD) INDUCES A HIGH RESPONSE RATE WITH DURABLE RESPONSE RATE AND DURABLE RESPONSES IN PATIENTS WITH REFRACTORY MULTIPLE MYELOMA (MM).

A PHASE 1V STUDY TO ASSESS THE COMBINATION OF SELINEXOR AND DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORYMULTIPLE MYELOMA PREVIOUSLY EXPOSED TO PROTEOSOME INHIBITORS (PI) AND IMMUNOMODULATORY DRUGS (IMIDS).

A PHASEIB/II TRIAL OF SELINEXOR COMBINED WITH LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA.

A PHASEIB/II TRIAL OF SELINEXOR COMBINED WITH LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA.

A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY OF DARATUMUMAB MONOTHERAPY FOR PATIENTS WITH INTERMEDIATE OR HIGH-RISK SMOLDERING MULITPLE MYELOMA (SMM): CENTAURUS.

THE MYELOMA CANADA RESEARCH NETWORK CANADIAN MULTIPLE MYELOMA DATABASE (MCRN CMM-DB): MULTI-INSTITUTIONAL SHARING OF CLINICAL DATA FOR RESEARCH.

CARDIAC REHABILITATION IN LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOETIC STEM CELL TRANSPLANTATION: A CARDIOONCOLOGY PILOT STUDY.

Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model.

Characterisation of Clonal Lymphocyte Biology in Malignancy

Immuno-oncologic Landscape in B-Cell Malignancies in Search of Novel Therapeutic Targets

Novel MYC Immunohistochemistry Classifier to Predict MYC Translocation by Fluorescence In Situ Hybridization in Diffuse Large B-Cell Lymphoma

Targeting DNA Repair Pathways for Multiple Myeloma